ArticleEpidemiologia (Basel, Switzerland)2026
Deaths Mentioning Both Pancreatic Cancer and Renal Failure in the United States, 1999-2024: Temporal Trends and Disparities.
Article in Epidemiologia (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe examined temporal trends in deaths mentioning both pancreatic cancer and renal failure in the United States.
methodsWe analyzed CDC WONDER multiple-cause-of-death data for adults aged ≥25 years from 1999 to 2024. Age-adjusted mortality rates (AAMRs) were assessed using Joinpoint regression. Secondary analyses quantified renal-failure co-recording among pancreatic-cancer-involving deaths, renal-failure subtypes, disparities, and comparisons with lung and bronchus, colorectal, and liver and intrahepatic bile duct cancers.
resultsOverall, 31,497 deaths mentioned both conditions. The AAMR increased from 0.37 per 100,000 in 1999 to 0.82 in 2024, with the most rapid increase during 2018-2024 (annual percentage change, 10.77%; 95% CI, 7.18-18.22%). Renal failure was co-recorded in 2.98% of pancreatic-cancer-involving deaths. Corresponding proportions were 2.37% for lung and bronchus, 4.75% for colorectal, and 5.77% for liver and intrahepatic bile duct cancer; recent trends did not differ significantly from pancreatic cancer. Acute kidney failure was the most frequently recorded renal subtype (43.22%). In 2024, AAMRs were higher among males and highest among non-Hispanic Black individuals.
conclusionsRenal-failure co-recording with pancreatic cancer increased markedly after 2018 but was not unique to pancreatic cancer. Death-certificate data do not establish temporal sequence or causality; linked clinical data are needed to clarify potentially modifiable kidney-related pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.